April 9th, 2015
Selections from Richard Lehman’s Literature Review: April 9th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include the PROMISE trial, the efficacy of folic acid therapy in primary prevention of stroke among patients with hypertension in China, and more.
April 9th, 2015
Association Between Shorter Height and Heart Disease Largely Explained by Genes
Nicholas Downing, MD
The “well-established” link between shorter adult height and increased risk for coronary artery disease (CAD) is largely explained by height-associated genetic variants, researchers conclude in the New England Journal of Medicine. Using data from genome-wide association studies, the researchers examined the relationship between 180 height-associated genetic variants and CAD among 65,000 cases (adults with histories of […]
April 6th, 2015
Bringing Clarity and Consensus to the Treatment of Hypertension in Patients with CAD
Elliott Antman, MD
AHA President Elliott Antman discusses the recent scientific statement from the AHA/ACC/ASH on the treatment of hypertension in patients with existing CAD.
December 8th, 2014
Selections from Richard Lehman’s Literature Review: December 8th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include the surgical treatment of moderate ischemic mitral regurgitation, the Mediterranean diet and telomere length, and more.
November 4th, 2014
Nonobstructive Coronary Artery Disease Linked to Elevated Risk
Larry Husten, PHD
A large number of people who undergo elective coronary angiography are found to have nonobstructive coronary artery disease, and these patients have significantly increased risk for myocardial infarction and death, according to a retrospective study published in JAMA. Thomas Maddox and colleagues analyzed data from nearly 38,000 elective angiography patients in the VA health system. More than […]
October 20th, 2014
Selections from Richard Lehman’s Literature Review: October 20th
Richard Lehman, BM, BCh, MRCGP
This week’s topic is the safety of adding nitrous oxide to general anesthesia in patients with known or suspected coronary artery disease who are having major non-cardiac surgery.
August 31st, 2014
SIGNIFY Trial Provokes Sound and Fury Over Controversial Drug
Larry Husten, PHD
The already controversial drug ivabradine just got a little more controversial. The drug, which is marketed by Servier under the brand names of Corlentor and Procoralan, is available in Europe and elsewhere and is used for the treatment of heart failure and stable angina. The drug is not available in the U.S., but it is under development by Amgen for a […]
May 27th, 2014
Selections from Richard Lehman’s Literature Review: May 27th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include mortality trends in patients with diabetes, cardiovascular remodeling in CAD and HF, and more.
January 30th, 2013
How Insurance Status Affects Treatment for Patients with CAD
Kim G. Smolderen, PhD, Paul S. Chan, MD, MS and John Ryan, MD
Does a patient’s insurance status affect a physician’s decision to prescribe evidence-based therapies for CAD?
November 19th, 2012
Comprehensive Guidelines for Stable Ischemic Heart Disease Released
Larry Husten, PHD
New comprehensive guidelines for the diagnosis and treatment of stable ischemic heart disease have been released by the ACCF/AHA Task Force on Practice Guidelines.
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?